Can CNS trial momentum convert into late-stage evidence?
CNS trial activity remains broad and globally distributed, but GlobalData clinical trials data shows development is still concentrated in planned, recruiting and Phase II studies. With pain driving the largest share of trial volume and Asia-Pacific leading regional activity, the key 2026 question is whether this momentum can translate into greater Phase III depth.
